Fulvestrant plus CDK4/6 inhibitors are recommended as the preferred second- and subsequent-line treatment for HR+/HER2- advanced breast cancer, subject to the most updated National Comprehensive Cancer Network (NCCN) guideline 2020 (6). This evidence concerns the gene ERBB2 and breast cancer.